Vela Diagnostics Sequencing System for HIV-1 Genotype Testing
Inactive on SAM.gov — responses were due 27 Aug 2026 · Unrestricted (full and open) · Defense Health Agency (DHA), DoD · Silver Spring, MD · NAICS 325413 · Solicitation HT9426-26-NOI-5892
Following NAICS 325413? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 27 August 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
Notice of Intent (NOI) to Sole Source Title: Vela Sentosa SQ Next Generation Sequencing (NGS) for FDA Approved HIV-1 Genotype Sequencing Requiring Activity: Walter Reed Army Institute of Research (WRAIR) , Diagnostics and Countermeasures Branch (DCB) Related Notice: HT9426-26-RFI-5892 Product Service Code (PSC): 6550 - In Vitro Diagnostic Substances, Reagents, Test Kits and Sets North American Industry Classification System (NAICS) Code: 325413 - In-Vitro Diagnostic Substance Manufacturing Small Business Size Standard: 1250 employees The Defense Health Agency Contracting Activity (DHACA) on behalf of the Diagnostics and Countermeasures Branch (DCB) at the Walter Reed Army Institute of Research (WRAIR) intends to award a Firm Fixed Price contract on a sole source basis to Vela Diagnostics, USA INC; 353C US Highway 46; STE 250; Fairfield, New Jersey 07004; Cage Code 86YT5 under the RFO FAR 6.103-1 Only one responsible source can supply the required products, and no other type of supplies or services will satisfy requirements. Description of Services: Via a reagent rental agreement, the contractor shall provide all Sentosa sequencer kits, consumables, supplies, sequencing systems and sub-components, and maintenance and repair. The HIV Diagnostics and Reference Lab (HDRL), DCB at the WRAIR currently utilizes the Sentosa SQ Next Generation Sequencing (NGS) system in order to perform HIV genotype testing which is critical for the monitoring of drug resistance mutations in HIV-1 infected soldiers and their beneficiaries. The Sentosa NGS system includes instrumentation and reagents required to perform the Vela Sentosa SQ HIV-1 Genotype test in a College of American Pathologist (CAP) accredited laboratory. As the system and assay is Food and Drug Administration (FDA) approved, clinical testing laboratories are required to use the instruments and reagents approved by the FDA in the execution of the test. Market Research was conducted and indicated similar products from other companies cannot meet or be modified to meet the Government s requirements. Additionally, this contract requires a reagent rental agreement between the manufacturer and the Government. Vela has confirmed that authorized third party vendors of Vela products are not authorized to offer this agreement; ergo, the requirements of this contract can only be met by Vela. This special notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no meaningful, written submissions are received by the date listed below, after the publication of this notice, the solicitation will be issued as a sole source requirement to Vela Diagnostics, USA INC. Based on the above information, the only technically acceptable vendor to fulfill this requirement is Vela Diagnostics, USA INC. Submit capability statements (using PDF, MS Word, or Excel attachments) to Ms. Brenda Mena at e-mail: brenda.i.mena.civ@health.mil. Capability statements are due no later than 10:00am Eastern Daylight Time on 27 August 2026. No phone calls will be accepted
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
